Amyloidosis, Hereditary
11 clinical trials · Condition
◉ Watch Amyloidosis, Hereditary
| Record | Firm | Date |
|---|---|---|
| HELIOS-A: A Study of Vutrisiran (ALN-TTRSC02) in Patients With Hereditary Transthyretin Amyloidosis (hATTR Amyloidosis) (NCT03759379) | Alnylam Pharmaceuticals | 2019-02-14 |
| ENDEAVOUR: Phase 3 Multicenter Study of Revusiran (ALN-TTRSC) in Patients With Transthyretin (TTR) Mediated Familial Amyloidotic Cardiomyopathy (FAC) (NCT02319005) | Alnylam Pharmaceuticals | 2014-12-01 |
| APOLLO: The Study of an Investigational Drug, Patisiran (ALN-TTR02), for the Treatment of Transthyretin (TTR)-Mediated Amyloidosis (NCT01960348) | Alnylam Pharmaceuticals | 2013-11-01 |
| Expanded Access Protocol of Patisiran for Patients With Hereditary ATTR Amyloidosis (hATTR) (NCT02939820) | Alnylam Pharmaceuticals | |
| ATTR Expanded Access Program (EAP) by Ionis (NCT03400098) | Ionis Pharmaceuticals, Inc. |
Track Amyloidosis, Hereditary automatically
Every clearance here is in the API, with alerts when new ones post.